NY-MOODY’S-ANALYTICS
4.6.2020 13:02:06 CEST | Business Wire | Press release
Moody’s Analytics, a global provider of financial intelligence, ranks #1 in 14 international categories in the 2020 FocusEconomics Analyst Forecast Awards. These awards include #1 Best Overall Forecaster – Hong Kong, plus the top ranking in five other forecast categories across 12 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200604005200/en/
#1 Best Overall Forecaster – Hong Kong
#1 Interest Rate Forecaster – Austria
#1 Interest Rate Forecaster – Italy
#1 Interest Rate Forecaster – Portugal
#1 Interest Rate Forecaster – Bahrain
#1 Inflation Forecaster – Belgium
#1 Inflation Forecaster – Malaysia
#1 Current Account Forecaster – Brazil
#1 Current Account Forecaster – Uruguay
#1 Fiscal Balance Forecaster – Croatia
#1 Fiscal Balance Forecaster – Peru
#1 GDP Forecaster – Malaysia
#1 GDP Forecaster – Slovenia
#1 GDP Forecaster – Tunisia
We also took second or third place in an additional 29 categories including:
#2 Best Overall Forecaster – Singapore
#2 GDP Forecaster – Brazil
#3 Best Overall Forecaster – Japan
“We’re pleased to earn this recognition from FocusEconomics, as it directly reflects the accuracy of our economic forecast scenarios,” said Cris deRitis, Deputy Chief Economist at Moody’s Analytics. “Our clients need trustworthy forecasts now more than ever, and can rely on ours to manage risk, implement accounting standards, and make strategic decisions with confidence.”
With the help of the Moody’s Analytics Global Macroeconomic Model, our economists generate economic forecasts for more than 100 countries interlinked by trade flows, financial markets, prices, and investments. Each month, the baseline scenario projects our view of the most likely path for the global economy, while a further 11 forecast scenarios project alternative economic paths under different assumptions.
To help users, each scenario is assigned a probability based on its relative severity. They are available for download in various file formats, through an Excel Add-In, via API programmatically, or by custom delivery. Clients can also adjust the forecast assumptions and create their own scenarios using the Moody’s Analytics Scenario Studio platform, which supports rigorous governance processes and real-time collaboration among multiple users.
To determine its annual rankings, FocusEconomics examines the accuracy of forecasts submitted to its monthly survey over a 22-month period. Their survey covers 89 countries (on six main macroeconomic indicators) as well as 22 commodities. Our results in this year’s rankings reflect the accuracy of our macroeconomic forecasts for those key indicators between January 2018 and October 2019.
Learn more about this recognition, which adds to the growing list of awards and accolades for Moody’s Analytics.
About Moody’s Analytics
Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter or LinkedIn .
Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.8 billion in 2019, employs approximately 11,300 people worldwide and maintains a presence in 40 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200604005200/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom